Google
Trusted Resources: News & Meetings
Latest announcements and gatherings
Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks
CARLSBAD, Calif., April 24, 2023 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the Phase 3 NEURO-TTRansform study for AstraZeneca and Ionis’ eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) met all co-primary endpoints and secondary endpoints at 66 weeks versus an external placebo group. The positive results are being presented today in an Emerging Science Session at the American Academy of Neurology (AAN) 2023 Annual Meeting in Boston. ATTRv-PN is a debilitating disease driven by the progressive accumulation of TTR amyloid deposits, which causes progressive nerve damage and leads to organ failure and eventually death.
myBinderRelated Content
-
FDA Approves Alnylam’s Onpattro for Polyneuropathy of hATTR AmyloidosisThe FDA today granted Alnylam Pharmaceut...
-
The Judy and Bernard Briskin Center for Multiple Myeloma Research, City of HopeCity of Hope is committed to beating thi...
-
Informed Consent for Clinical TrialsThe term informed consent is mistakenl...
-
The Coverage Battle Continues for Veterans With Transthyretin AmyloidosisThe Veterans Health Administration exist...
-
The Peripheral Nerve Center at Johns HopkinsThe Peripheral Nerve Center at Johns Hop...
-
Transthyretin Amyloidosis (ATTR): Rare Disease Prevalent in the Portuguese Communityhttps://www.oneamyloidosisvoice.com/wp-c...
-
Intellia Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022Intellia Therapeutics, Inc. (NASDAQ:NTLA...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Community Key Collaborator
Support for this landing page is provided by an independent education grant from
Translation of this platform made possible through an independent education grant from
Powered by
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
